Feb 24 2024University at Buffalo
A University at Bufalo-led research team hopes to add to that number. It is developing a new recombinant flu vaccine – described in a study published today in the journal Cell Reports Medicine – that has the potential to compete with existing vaccines. Conventional flu vaccines contain either deactivated microbes that cause influenza, or they are based on weakened forms of the disease. They are made using fertilized chicken eggs or, less commonly, through cell culture-based production.
In the new study, the team attached to the nanoliposome a total of six proteins – three each from two different protein groups, hemagglutinins and neuraminidases. The team also added two adjuvants to boost immune response. The tests were performed via vaccination and through blood serum transfer from vaccinated mice into non-vaccinated mice.